Proteintech, 14631-1-AP-150ul, AFG3L2 Polyclonal antibody

14631-1-AP targets AFG3L2 in WB, IHC, IF/ICC, IP, ELISA applications and shows reactivity with human, mouse, rat samples.
Tested Applications
Positive WB detected in: HeLa cells, mouse skeletal muscle tissue, mouse kidney tissue, Jurkat cells, mouse brain tissue, mouse liver tissue, rat liver tissue
Positive IP detected in: HeLa cells
Positive IHC detected in: human kidney tissueNote: suggested antigen retrieval withTE buffer pH 9.0;(*) Alternatively, antigen retrieval may be performed withcitrate buffer pH 6.0
Positive IF/ICC detected in: HepG2 cells, HeLa cells
Recommended dilution
Western Blot (WB): WB : 1:2000-1:16000
Immunoprecipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC): IHC : 1:100-1:400
Immunofluorescence (IF)/ICC: IF/ICC : 1:10-1:100
Background Information
AFG3L2 is the catalytic subunit of the m-AAA protease, an ATP-dependent proteolytic complex of the mitochondrial inner membrane that degrades misfolded proteins and regulates ribosome assembly(PMID:17101804). Human AFG3L2 is an 80-kDa protein encoded by a 17-exon gene and highly and selectively expressed in human cerebellar Purkinje cells(PMID:20208537) and it can exsit as a truncated 65 kDa protein(PMID:18337413). Defects in AFG3L2 are the cause of spinocerebellar ataxia type 28 (SCA28) and spastic ataxia autosomal recessive type 5 (SPAX5).